Kamran Alam, CPA, MBA

SVP, Finance

Kamran has nearly 15 years of experience in the biotechnology industry.  Most recently, Kamran was Vice President, Finance at AveXis, Inc. for 3.5 years where he established and built a finance team.  While at AveXis, Kamran led Financial Planning and Analysis, Procurement and Risk Management functions.  At AveXis, Kamran also played a pivotal role in successfully executing and closing multiple follow-on financing transactions and in Novartis’ acquisition of AveXis for $8.7 billion.  Following Novartis’ acquisition of AveXis, he was appointed Deputy Chief Financial Officer and supported the development and commercialization of Zolgensma and advancement of AveXis’ gene therapy pipeline programs. 

His prior biotech industry experiences include Senior Director, Finance and Accounting at Aptinyx, where Kamran held a leadership role in the finance and accounting team.  He was also Director of Finance at Naurex, culminating in Allergan’s acquisition of Naurex.  Earlier in his career, Kamran held various finance and project management roles with increasing responsibility at Ovation Pharmaceuticals, Lundbeck and Fresenius Kabi. 

Kamran received his Bachelor of Business Administration degree with High Distinction from the Ross School of Business at University of Michigan and MBA in Finance from the Kelley School of Business at Indiana University.  Kamran is a Certified Public Accountant. 

Kamran is on the Board of Trustees at Huntington’s Disease Society of America (HDSA).  He is passionate about working at organizations that focus on innovative, life-saving new therapies to help people lead longer and healthier lives. 

Back to Management